Patent · US Expired

Substituted pyrazoles as p38 kinase inhibitors

US6617324B1 · kind B1 · utility

28Cited by

14References

112Claims

0Family size

Assignee

G.D. Searle LLC · US

Inventors

Ashok S. Naraian · Ballwin, US
Michael Clare · Skokie, US
Paul W. Collins · Deerfield, US
Joyce Z. Crich · Glenview, US
Rajesh Devraj · Chesterfield, US
Daniel L. Flynn · Lawrence, US
Lifeng Geng · Skokie, US
Matthew J. Graneto · Chesterfield, US
Cathleen Hanau · Chesterfield, US
Gunnar J. Hanson · Cambridge, US
Susan J. Hartmann · Kirkwood, US
Michael Hepperle · Boston, US
He Huang · Northbrook, US
Francis J. Koszyk · Prospect Heights, US
Shuyuan Liao · Northbrook, US
Suzanne Metz · Chesterfield, US
Richard A. Partis · Evanston, US
Thao Perry · San Jose, US
Shashidhar N. Rao · Chesterfield, US
Shaun Raj Selness · Chesterfield, US
Michael S. South · Chesterfield, US
Michael A. Stealey · Libertyville, US
John J. Talley · Chesterfield, US
Michael L. Vazquez · Saint Louis, US
Richard M. Weier · Lake Bluff, US
Xiangdong Xi · Evanston, US
Ish Khanna · Vernon Hills, US
Yi Yu · Skokie, US

Key dates

Filing date	Apr 2, 2002
Grant date	Sep 9, 2003
Priority date	—
Expiry date	May 20, 2022

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

A class of pyrazole derivatives described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.